Captor therapeutics7/1/2023 ![]() The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested performance is not an indicator of future actual results. +41 (0)76 735 01 A prodrug is a biologically inactive compound which can be metabolized in the body to produce a drug which is pharmacological active.Cash, Cash Equivalents and Short-Term Investmentsĭisclaimer: The TipRanks Smart Score performance is based on backtested results. LinkedIn: and investor contacts: Polish Media and Investor Relations: Captor is currently developing treatments for undertreated serious conditions, including cancer and autoimmune diseases.įor more information on Captor Therapeutics, visit : TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered undruggable" using classical drug modalities and provide additional treatment options for diseases where existing drugs do not provide optimal treatment. Potent degradation and first-in-class selectivity profile of the molecular target PKCӨ in immune cells in vitroĬaptor Therapeutics is a drug discovery and development company applying targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases with significant unmet medical need.In preclinical studies, CT-05 has demonstrated attractive features that differentiate CT-05 from inhibitors that failed in clinical trials due to side effects: the potential of the PKCӨ protein pathway is underpinned by BMS's latest in-licensing of Exscientia's PKCӨ inhibitor EXC4318.The IL-17 pathway is a clinically validated pathway in autoimmune diseases such as psoriasis with established modulators 2 the PKCӨ protein acts via the CD3/CD28 – IL-2/IL-17 pathway.Importantly, the approach behind CT-05 is partially de-risked thanks to: PKCӨ is a high-value target with opportunities in certain autoimmune diseases, such as allergy, psoriasis, and inflammatory bowel disease, as well as certain malignancies, such as breast and gastrointestinal cancer. It is therefore expected that degrading the PKCӨ protein would lead to an increased T cell suppressive function. Indeed, PKCӨ plays an important role in the modulation of T cells by limiting the suppressive function of T cells. Compounds with the ability to cross the blood-brain-barrier have been identified and provide opportunity for further development in the area of neurodegenerationĬT-05 targeting (new disclosure) PKCӨ (PKC theta)ĬT-05 targets the PKCӨ protein, a protein highly relevant in both autoimmune diseases and cancer.Optimised compounds with good pharmacokinetics in animals have been developed.Degradation of NEK7 is correlated with the desired in-vitro biological effects on the inflammatory response.Effective NEK7 degradation at low concentrations in vitro (high potency) and ex vivo.Pre-clinical studies have revealed the following benefits of CT-02: It is therefore expected that selective degradation of NEK7 would also remove the NEK7 scaffolding function leading to potent inflammatory inhibition. Importantly, it is established that NEK7 pro-inflammatory activity is largely driven by its scaffolding function, and because of that, classical inhibition of NEK7's kinase function doesn't provide therapeutic benefit. Such NEK7 degradation allows the modulation of the inflammasome, a complex that plays a critical role in the regulation of the inflammatory response.Ĭaptor believes that selective NEK7 degraders have the potential to overcome the limitations shown in the past of NLRP3 inhibitor drugs related to increased susceptibility to infection. In addition to the potential benefits of NEK7 degradation combined with the degradation of GSPT1 and SALL4 in cancer, as mentioned above for the CT- 01 Project, the selective degradation of NEK7 alone in the CT-02 Project has many potential benefits as a treatment of several autoimmune diseases. Moreover, CPT-6281 is particularly well suited for liver, lung, and neuroendocrine tumors since it is a prodrug 1 activated by an enzyme present in high concentration in the liver, the lungs, and some gastrointestinal tumors. GSPT1 is a protein involved in the termination of translation, SALL4 is a transcription factor often over-expressed in HCC patients and correlating with poor prognosis, and NEK7 is a protein in which degradation leads to a reduction in IL-1b production, a well-known pro-carcinogenic factor. ![]() The first indication will be in Hepatocellular Carcinoma (HCC).ĬPT-6281 is a first-in-class degrader of GSPT1, SALL4, and NEK7. CT-01 / CPT-6281 targeting GSPT1, SALL4 and (new disclosure) NEK7ĬT-01 / CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of 2023. ![]()
0 Comments
Leave a Reply. |